by Mark Curtis | Dec 30, 2015
Welcome to your Cell Therapy Deal Review for the month of November. Astellas failed to achieve the majority share it needed to push through a takeover of Ocata Therapeutics valued at $379 million. ImmunoCellular Therapeutics announced a research agreement with MD...
by Mark Curtis | Dec 28, 2015
For those of you that missed ISCT’s recent webinar on manufacturing, needle-to-needle logistics and reimbursement, below is a brief re-cap of the key points on the reimbursement section that I provided. The presentation, including audio, should be available free on...
by Mark Curtis | Dec 10, 2015
Welcome to your Update from the Clinic for the month of November. There were a number of mid-stage clinical trials launched by cell-based immunotherapy companies this past month, furthering a robust global pipeline of CAR/TCR products. We also saw some efficacy data...
by Mark Curtis | Nov 24, 2015
Welcome to your Cell Therapy Deal Review for the month of October. Lion Biotechnologies and Kite Pharma both made deals with the National Institutes of Health (NIH) that significantly expanded their respective pipelines. Kite also announced a research collaboration...
by Hamideh Emrani | Nov 4, 2015
Among many interesting talks at this year’s Till and McCulloch Meetings in Toronto, Canada, there were a couple related to biomaterials, which I’d like to focus on. In the first talk, professor Milica Radisic, University of Toronto, talked about two recent...
Comments